NHC Raises Its Dividend Again, but at $220 a Share, the Income Case Has Changed

National HealthCare Corporation raised its quarterly dividend to 67 cents per share in May 2026, a 4.7% increase over the 64 cents it had paid for three prior quarters. That marks the 12th consecutive year of dividend increases and the 22nd consecutive year of payments. The payout is safe. The cash-flow engine is humming. The balance sheet is the strongest it has been in years.

But the stock is trading near $220 a share and that price appreciation has compressed the forward yield to about 1.2%. The income investor's question is no longer whether NHC will keep paying. It's whether the math still works at these terms.

The cash-flow engine is real, not theoretical.

The balance sheet went from manageable to fortress. Total debt dropped to debt reduced to $40M at the end of 2025. On adjusted net income of $104 million (excluding unrealized gains on marketable securities), it's closer to 40%. Either way, the company is spending less than half its earnings on dividends while running down debt.

That is the kind of coverage margin that separates a dividend you keep from one you watch nervously.

2025 was a genuine earnings year, not a one-off. Revenue grew 16.1% to $1.52 billion.

This is not a company papering over thin margins.

So what changed? The business didn't change today. The dividend didn't change today — the May increase was already priced in weeks ago. What changed is that the yield compressed from a useful 2%-plus into the 1.2% range. At that yield, NHC is no longer an income stock. It's a dividend growth story with a modest coupon attached.

That matters because the reason you hold NHC determines what you do now. If you bought it for income at $100 a share and a 2.5% yield, the payout is intact and the annual increases are compounding your cost basis down. The dividend keeps working. If you're shopping for yield today, 1.2% is thin. That's what you get from a Treasury with less risk and less hassle. The stock earns its place only if you believe the dividend keeps growing at 4–5% a year and the earnings power behind it sustains that trajectory.

The valuation supports some optimism but demands respect. NHC trades at roughly 26.5 times trailing earnings. A Seeking Alpha analyst in July called the 16.4 times EV/EBITDA multiple "rich" and flagged soft utilization as a watch item. None of these risks threaten the current dividend, but they cap how carefree you should be about adding size.

The portfolio verdict. For existing holders, there's nothing to do but collect the checks. The dividend is covered, the balance sheet is clean, the occupancy numbers are rising, and the payment mix is improving. If price volatility lets you reinvest at better terms, that's the play — buy more shares of a proven income engine, not because the business changed, but because the terms improved.

For new money looking for yield, NHC at $220 isn't the entry point. The 1.2% forward yield doesn't move a portfolio needle. The stock makes more sense as a dividend growth position than an income position, and at these multiples, you're paying for the growth assumption upfront. Wait for a pullback that restores a yield in the 1.8–2.0% range, or allocate your income dollars elsewhere and come back when the terms work for the income objective, not just the appreciation hope.

The dividend is safe. The business is better than it was. The price just got ahead of the income math.